Greetings and happy New Year!
Relatively new member. Have an update and would be grateful for any thoughts.
57 years old.
In July of this year I registered a PSA of 10.5 (taking Propecia for 18 years so the 5.25 reading gets multiplied by at least two). This was prompted by a Life Insurance exam and was my first PSA reading ever. My doctor suggested a biopsy but after spending time researching what folks do when presented with a high PSA I requested that she write me a script
for a 3T mpMRI. The results of that indicated two lesions (PIRADS 5 & PIRADS 4). I followed this with a Fusion Biopsy at a leading cancer center. Result was 3 of 16 positive for Gleason 6, two of the cores were targeted (both positive) and the remainder were "random" (one positive). Volume was 20, 15, & 10% of each core and all were on one side. Other data of relevance noted by the Urologist is a free PSA of 9%, and very high apparent PSA density given that my prostate is only 16cc's.
Armed with the above I approached another leading cancer center for a second opinion concerning both the MRI and the biopsy. Results of that upgraded one of the cores to Gleason 7 (3+4) and upgraded an additional core from ASAP to Gleason 6 (on the other side). Pattern 4 is 5%.
EDIT: AFTER RECEIVING THE PATHOLOGY REPORT IT ACTUALLY SHOWS 3 CORES AT 3+4 AND NOT JUST ONE. IN ADDITION CORE VOLUME INCREASED IN TWO CORES
MRI notes for both of the lesions: "broadly abuts the capsule without visualized gross EPE". Both are in the peripheral zone with one of the lesions in the anterior distal apex. Urologist in meeting also suggested some possible complications of the
locations. Both readings had a number of other cores that were HGPIN.
I have been doing a lot of research and taking my time as suggested by the above time line.
I landed on a very recent presentation by Dr. Klotz (thanks to this forum!!) to be very pertinent. From everything I read he is one of the pioneers in AS. In the presentation he outlines the boundary conditions and determinants of candidacy for AS, how they have evolved and how his recent data on his large cohort (since 1995) at the University of Toronto is affecting his view on when this is an appropriate strategy and when it is less so. In summary, Dr. Klotz data suggests a markedly higher risk associated with any pattern 4 irrespective of volume. He also suggests that PSA density is unquestionably highly correlated with upgrading. He did partitioning analysis of his AS folks by outcomes showing that for even the most favorable Gleason 7 (3+4) candidates (low PSA and low volume) that they had a 30% metastasis rate at 15 years. I also found related data-rich research from Michigan on the MUSIC AS pool that was also very relevant.
https://www.urotoday.com/video-lectures/advanced-prostate-cancer/video/778-embedded-media2017-06-02-13-54-01.html
I have also discovered by reading the good words in this forum that a prostate cancer diagnosis ultimately calls for the patient to making their own treatment choice.
Anyone in a similar situation or any thoughts related to the above?
Thanks!!
Post Edited (AJMan) : 1/19/2018 6:35:22 PM (GMT-7)